Fluor Corporation Common Stock vs uniQure N.V. Ordinary Shares — how do they compare? Fluor Corporation Common Stock trades at $47.6 (market cap $6.65B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: Fluor Corporation Common Stock is far larger — about 4.5× uniQure N.V. Ordinary Shares's market cap, and Fluor Corporation Common Stock is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fluor Corporation Common Stock for 6 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| FLR | QURE | |
|---|---|---|
Market Cap | $6.65B | $1.48B |
Volume | 1,556,536 | 2,488,780 |
Sector | Industrials | Health |
52-Week High | $57.50 | $70.59 |
52-Week Low | $39.63 | $9.03 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $4.68B | $728.62M |
Signals from Pluang's Aura AI — not financial advice
Fluor Corporation (FLR) trades at $49.75, showing minimal daily movement with a 0.08% gain. The stock faces bearish technical signals but maintains analyst support with a $62.33 consensus price target. Recent Q2 2026 earnings beat expectations, though profitability remains challenged with negative margins. The company secured a significant $7.5 billion LNG Canada Phase 2 project, providing substantial future revenue visibility amid ongoing operational restructuring.
FLR presents a turnaround opportunity with strong backlog coverage but carries execution risks. The stock trades at attractive valuation multiples (P/S 0.49) with 53.6% analyst buy ratings, yet negative cash flow and margin pressures require careful monitoring. Near-term performance hinges on successful project execution and margin improvement from the shift to reimbursable contracts.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Fluor provides engineering, procurement, construction, and maintenance services. It works across energy, infrastructure, mining, advanced technology, manufacturing, life sciences, and government projects.
Read more on FLR →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →